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volume targets in the IBCL seed group and the loose seed 
group. Brachytherapy was performed using a dynamic dose 
calculation technique. Computed tomography/magnetic 
resonance imaging fusion-based dosimetry was performed 1 
month after brachytherapy. Post-implant dose volume 
histogram (DVH) parameters, prostate sector dosimetry, 
operation time, seed migration, and toxicities were 
compared between the two groups. A sector analysis tool was 
used to divide the prostate into six sectors (anterior and 
posterior sectors at the base, mid-gland, and apex). Analyses 
were performed using the 2-sample t test for continuous data 
that followed a normal distribution, the Mann-Whitney test 
for continuous data that did not follow a normal distribution, 
and the Chi-squared test for categorical data. Probability (P) 
values of < 0.05 were considered significant. 
 
Results: In prostate sector dosimetry, V100 (95.3% vs. 89.7%; 
P = 0.014) and D90 (169.7 Gy vs. 152.6 Gy; P = 0.013) in the 
anterior base sector were significantly higher in the IBCL 
seed group than in the loose seed group. Other post-implant 
DVH parameters did not differ significantly between the two 
groups. The seed migration rate was significantly lower in the 
IBCL seed group than in the loose seed group (6% vs. 66%; P < 
0.001). There was no significant difference in mean operation 
time between the two groups; however, mean operation time 
per seed was significantly longer in the IBCL seed group than 
in the loose seed group (1.31 min vs. 1.13 min; P = 0.003). 
The median follow-up was 18 months (range, 1-36 months). 
No significant differences in toxicities were seen between the 
two groups. 
 
Conclusion: Our study showed more dose coverage post-
operatively in the anterior base prostate sector and less seed 
migration in IBCL seeds implantation compared to loose seeds 
implantation. 
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Purpose or Objective: to evaluate results of saturation 
biopsy in candidates for focal, hemigland high dose rate 
(HDR) brachytherapy or irradiation with “low-dose tunnel for 
urethra” 
 
Material and Methods: Template guided saturation biopsy 
was performed in 52 primary patients with suspicion to 
prostate cancer and PSA below 10 ng/ml. Biopsy was 
performed under US control with the help of brachytherapy 
grid and 5mm distance between samples. During positioning 
and biopsy procedure we put special attention for accurate 
sampling of prostate in periurethral region. The number of 
cores varied from 17 to 50 (average 33 cores). Finally in 31 
patients with confirmed prostate cancer results of biopsy 
were used for brachytherapy planning. 
 
Results: Saturation biopsy revealed prostate cancer in 31 of 
52 evaluated patients. Involved volume ranged from 5% to 
100% (average - 57%). Focal nature of PC diagnosed in 6 
(19.4%), multifocal – in another 25 (80.6%) patients. 
Hemigland invasion mentioned in 10 cases. Saturation biopsy 
detected PC in periurethral cores in 22 (70.9%) of 31 
evaluated patients: invasion of one core revealed in 1, 2 
cores – in 6, 3 and more cores – in another 14 cases. In 10 
patients extent of involvement in periurethral cores varied 
between 10% and 50%, in another 12 observations exceeded 
50%. According to results obtained on saturation biopsy we 
performed HDR brachytherapy with “urethra low dose 
tunnel” (D10ur≤80%) in 9 patients with noninvolved 
periurethral cores. Theoretically hemigland brachytherapy 
was possible in 10 of 31 evaluated patients. 
 
Conclusion: in low risk patients with prostate cancer results 
of template guided saturation biopsy can significantly 
influence strategy of HDR brachytherapy 
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Purpose or Objective: We presented a retrospective analysis 
in 11 patients with histological proven local-recurrent 
prostate cancer, undergoing salvage BT, treated between 
February 2009 and December 2014. 
 
Material and Methods: The previous radical treatments 
were: 3 Low dose rate BT (LDR-BT) (145 Gy), one combined 
treatment with external radiotherapy (EBRT) (45 Gy) and 
LDR-BT (100 Gy), and 7 EBRT (68-74 Gy). Four patients have 
been rescued with LDR-BT and seven with High-Dose-Rate-BT 
(HDR-BT). All patients have a complete study with abdominal 
CT scan, pelvic MRI, and bone scan to diagnose local disease 
exclusively. LDR-BT patients received 145 Gy with 125I. HDR 
patients, has been treated with 30 Gy in 3 fractions of 10 Gy 
separated ten days. Median time to Biochemical failure (BF) 
from the first treatment was 48 months (12-114). All patients 
received previous hormonotherapy. Median time to rescue 
was 69 months (33-156). Toxicities were evaluated according 
with CTCAE scale (version 4.0). 
 
Results: Median follow-up: 26,5 months (3-72 m). The overall 
survival time was 98 months (65-174). At the end of the 
follow up, March of 2015, all patients are alive, nine (82%) 
without evidence of disease, one patients had a 
retroperitoneal failure 7 months after the salvage-BT and 
other patient was diagnosed of a solitary bone metastases at 
12 months. Median PSA nadir post-salvage-BT was 0.1 ng/ml 
(0-0,29). There were not grade 3 GU or GI toxicities. 100 % of 
LDR-BT patients presented acute GU-toxicity grade 2. Fifty-
seven % of the HDR-BT patients had GU-toxicity grade 1 (0% 
grade 2). 
 
Conclusion: Prostate BT is an effective and well tolerated 
reirradiation treatment in local-recurrent prostate cancer 
patients, with, few long-term toxicities, mainly in those 
treated with HDR-BT. 
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Purpose or Objective: The different conventional treatments 
for prostate cancer are multiple and for low-risk tumors, 
focal brachytherapy can be a therapeutic alternative option 
to active surveillance. However, this focal treatment remains 
still under evaluation and within the frame of the focal 
brachytherapy project conducted in Toulouse, we will 
present in this study two parts of the project: first, the 
contribution of multi-modal rigid and non-rigid registrations 
for localization and delineation of the treated volume, then 
the dosimetry evaluation after registration. 
 
Material and Methods: First step of prostate brachytherapy 
at our Institute consists in a contour-based non-rigid 
registration between MRI and US perfomed with Koelis 
software where positive biopsy trajectory is retrieved and a 
fiducial non-radioactive marker is implanted to localize the 
tumor focus. As a result of this localization, dosimetry was 
performed using VariSeed software, dose prescription is 
